Vanguard Pharmaceutical Corp. Corporation Forms Team in Peru

SAN ANTONIO, TX--(Marketwire - January 07, 2009) -

Vanguard Pharmaceutical Corp. (PINKSHEETS: VGPH), a company who has joined the fight against cancer by selling affordable generic oncology drugs and researching noninvasive cures for cancer has recently visited Lima, Peru to form a sales and marketing team and conduct further research on the market.

Vanguard’s president, Raul Fernandez, was pleased with the business trip stating, “We believe we have found the key people who have the experience to ensure our success in the Peruvian oncology market.” The newly formed team has three members with significant experience in the field. Mr. Rodriguez has almost 50 years of pharmaceutical management experience often overseeing the introduction and promotion of new pharmaceutical products. Mr. Pando has 35 years experience in the industry and 20 years experience in the oncology field. He has worked as a product specialist advising professionals in the field on oncology drugs. Mr. Rodriguez’s son, Ernesto has also worked 5 years in pharmaceutical sales and promotions and will also be a strong player to the team.

www.vanguardpharm.com

About Vanguard Pharmaceutical

In an era of aging populations, rising health care costs, and increasing cancer cases Vanguard’s mission is to decrease health care expenditures by selling affordable oncology and generic drugs and by investing in research to find a noninvasive cure for cancer.

Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure. Vanguard is currently targeting Latin America for its oncology and generic pharmaceutical sales as it is believed to have a substantially unmet demand for advanced generics and entry into the market can be done with relative ease. Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009.

A noninvasive cure for cancer will revolutionize our health care system by highly reducing hospital stays as patients will not have to go through life threatening chemotherapy and radiation which could save health care systems billions of dollars. Vanguard’s team is researching several new technologies such as telomerase inhibitor therapy, nanoparticle therapies, and low power radio frequency radiation. Vanguard plans to partner with established clinical centers and universities to further develop these technologies then license them out. It has also discussed performing trials in Latin American oncology centers.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.